Craig-Hallum raised the firm’s price target on Exact Sciences (EXAS) to $85 from $65 and keeps a Buy rating on the shares. The firm would be a buyer of Exact Sciences. With the Freenome deal in place and Shield V2 data out, Craig-Hallum thinks the Street will begin to focus on execution. With a stable of incremental near-term revenue growth drivers, prospects for continued EBITDA margin expansion, substantially improving cash flow, and potential upside to estimates, the stock could break out of this two-year cycle, argues the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences launches Cancerguard test in the U.S.
- Promising Growth Prospects for Exact Sciences: Buy Rating Justified by Strong Cologuard Performance and Strategic Initiatives
- Cathie Wood Buys Deere Stock (DE) on Post-Earnings Dip, Builds Stakes in Exact Sciences and Robinhood Stocks
- Cathie Wood’s ARK Investment buys 298K shares of Exact Sciences today
- Exact Sciences price target lowered to $60 from $65 at BTIG